MedinCell And 2 Other Top Growth Stocks With Strong Insider Ownership
Reviewed by Simply Wall St
In the midst of a volatile global market landscape, characterized by fluctuating sector performances and shifting economic policies, investors are seeking stability and potential growth opportunities. One strategy gaining attention is focusing on growth companies with high insider ownership, as these stocks often indicate strong confidence from those closest to the company's operations and future prospects.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 43% |
| On Holding (NYSE:ONON) | 31% | 29.7% |
| Pharma Mar (BME:PHM) | 11.8% | 56.4% |
| Findi (ASX:FND) | 34.8% | 64.8% |
| Alkami Technology (NasdaqGS:ALKT) | 11% | 98.6% |
| Elliptic Laboratories (OB:ELABS) | 26.8% | 103.6% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 13.8% | 95% |
| Plenti Group (ASX:PLT) | 12.8% | 107.6% |
| EHang Holdings (NasdaqGM:EH) | 32.8% | 81.4% |
| Brightstar Resources (ASX:BTR) | 16.2% | 84.6% |
Let's take a closer look at a couple of our picks from the screened companies.
MedinCell (ENXTPA:MEDCL)
Simply Wall St Growth Rating: ★★★★★★
Overview: MedinCell S.A. is a pharmaceutical company based in France that develops long-acting injectables across various therapeutic areas, with a market cap of approximately €507.87 million.
Operations: The company's revenue primarily comes from its Pharmaceuticals segment, totaling €11.95 million.
Insider Ownership: 15.8%
Earnings Growth Forecast: 92.2% p.a.
MedinCell is positioned for significant growth, with revenue forecasted to increase by 50.6% annually, outpacing the French market. The company is expected to become profitable within three years and trades significantly below its estimated fair value. Recent strategic collaborations, notably with AbbVie and Teva, bolster its innovative long-acting injectable technology platform. Governance changes include a new Board of Directors and CEO appointment, potentially enhancing strategic direction and execution capabilities.
- Delve into the full analysis future growth report here for a deeper understanding of MedinCell.
- Insights from our recent valuation report point to the potential undervaluation of MedinCell shares in the market.
Genomictree (KOSDAQ:A228760)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Genomictree Inc. is a biomarker-based molecular diagnostics company that develops and commercializes products for detecting cancer and infectious diseases, with a market cap of ₩361.65 billion.
Operations: The company generates revenue from its Cancer Molecular Diagnosis Business, contributing ₩1.93 billion, and from its Genomic Analysis and Other Business, which adds ₩109.21 million.
Insider Ownership: 16.1%
Earnings Growth Forecast: 107.8% p.a.
Genomictree is projected to achieve substantial growth, with revenue expected to rise by 90.5% annually, surpassing the South Korean market significantly. Although it currently lacks meaningful revenue (₩2 billion), it is anticipated to become profitable within three years and trades at a considerable discount to its fair value estimate. The company has no recent insider trading activity over the past three months and reports its Q3 2024 results today.
- Dive into the specifics of Genomictree here with our thorough growth forecast report.
- Our expertly prepared valuation report Genomictree implies its share price may be lower than expected.
Guangdong Guanghua Sci-Tech (SZSE:002741)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Guangdong Guanghua Sci-Tech Co., Ltd. is a Chinese company that produces and sells electronic chemicals, chemical reagents, and new energy materials, with a market cap of CN¥6.98 billion.
Operations: The company generates revenue primarily from the Chemical Industry segment, amounting to CN¥2.53 billion.
Insider Ownership: 38%
Earnings Growth Forecast: 122.2% p.a.
Guangdong Guanghua Sci-Tech is experiencing a turnaround, reporting net income of CNY 6.78 million for the first nine months of 2024 compared to a significant loss last year. Despite past shareholder dilution, its revenue is forecasted to grow rapidly at 31% annually, outpacing the Chinese market. The company recently raised nearly CNY 700 million through private placements, indicating strong institutional interest but lacks recent insider trading activity over the past three months.
- Get an in-depth perspective on Guangdong Guanghua Sci-Tech's performance by reading our analyst estimates report here.
- Our expertly prepared valuation report Guangdong Guanghua Sci-Tech implies its share price may be too high.
Next Steps
- Take a closer look at our Fast Growing Companies With High Insider Ownership list of 1547 companies by clicking here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SZSE:002741
Guangdong Guanghua Sci-Tech
Produces and sells electronic chemicals, chemical reagents, and new energy materials in China.
High growth potential with imperfect balance sheet.
